In this episode of Nothing Ventured, Aarish Shah sits down with Romain Clément, founder of AKA Science, to explore how AI, clinical data and drug discovery could transform the pharmaceutical industry. Romain shares the personal story behind AKA Science, following his own brain tumour diagnosis and the three years of research that led him from literature and philosophy into healthcare, pharmaceuticals and AI. He explains how the company has built technology designed to structure complex scientific data and uncover potential treatment options that might otherwise remain hidden. The conversation explores why having more data doesn't necessarily create more value for pharma, and why the real challenge is often the structure, quality, context and usability of that data. Romain explains how AKA Science approaches unstructured scientific information, clinical data and AI to identify connections and potential treatment pathways. They also discuss drug repurposing, off-label treatments and how existing drugs could potentially be identified for different patient groups and conditions. Romain explains how AKA Science aims to connect the interests of patients and pharmaceutical companies by uncovering opportunities within existing drug portfolios. The discussion then moves into AI, European technology and sovereignty. Romain shares his perspective on Europe's ability to compete with the US and China, the importance of compute and data centres, open-weight models, regulation and why Europe needs to move faster if it wants to remain competitive in the AI race. They also explore Europe's strengths in scientific research and early-stage innovation, alongside the challenges of commercialisation, bureaucracy and turning research breakthroughs into scalable companies. Finally, Romain explains why AKA Science prioritised scientific rigour, industry trust and profitability rather than following the traditional venture-backed growth model, and shares his contrarian belief that the first immortal person may already have been born. In this episode: AI and the future of drug discovery Romain Clément's journey from brain tumour patient to founder Building AKA Science AI and pharmaceutical research Clinical data and scientific knowledge Why big data failed pharma Structuring and contextualising scientific data AI-powered drug discovery Drug repurposing and off-label treatments Finding overlooked treatment options Connecting patients and pharmaceutical companies Healthcare innovation and patient outcomes Data quality, noise and serendipity AI, compute and data centres Open-weight vs closed-weight AI models European AI sovereignty The US, China and Europe's AI race Regulation vs technological progress Europe's strengths in scientific research Commercialising European innovation Bureaucracy and the pace of innovation Building a healthcare technology company Profitability vs venture capital Trust and validation in pharma Scientific rigour and industry expertise The future of AI and healthcare Healthspan, longevity and immortality Find Romain Clément and AKA Science online at: AKA Science: https://akascience.com/ 🎙️ Listen to Nothing Ventured for conversations with founders, investors and the people shaping the future of technology and venture capital. #AI #ArtificialIntelligence #DrugDiscovery #Pharma #HealthcareAI #HealthTech #Biotech #Pharmaceuticals #DeepTech #VentureCapital #Startups #DrugRepurposing #ClinicalResearch #AIInnovation #HealthcareInnovation Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.
Show more
Show less